Top Industry Leaders in the Pain Patch Market
Latest Pain Patch Companies Update:
ACADIA Pharmaceuticals: Acquired CerSci Therapeutics Inc. in October 2023, gaining access to promising non-opioid pain medication candidates for patch delivery.
Grünenthal GmbH: Completed Phase 3 trials for Qutenza (lidocaine patch) for diabetic peripheral neuropathy, marking a potential non-opioid option for this prevalent condition.
Zogenix: Successfully tested ZX004, a novel non-opioid patch for neuropathic pain, in a Phase 2 trial, showcasing its potential for future development.
Purdue Pharma L.P.: Filed for bankruptcy in 2019 amidst the opioid crisis and ongoing lawsuits, impacting the distribution of OxyContin patches.
List of Pain Patch Key companies in the market
- LTS Lohmann Therapie-Systeme AG (Germany)
- (US)
- Mylan N.V.(US)
- Pfizer, Inc. (US)
- Teva Pharmaceutical Company (Allergan Plc (Actavis)) (Israel)
- Endo Pharmaceuticals Inc (Israel)
- Hisamitsu America, Inc. (America)
- Johnson & Johnson (US)
- Teikoku Seiyaku Co., Ltd (Japan)
- Sanofi (France)
- NICHIBAN Co (Japan)
- The Mentholatum Company (US)